The T2Bacteria Panel can detect sepsis-causing bacterial pathogens directly from whole blood. Credit: Tatiana from Pixabay.

T2 Biosystems has announced a collaboration with US-based Vanderbilt University Medical Center’s (VUMC) Learning Healthcare System Platform to assess the T2BacteriaPanel for clinical applications.

As part of the collaboration, VUMC will be responsible for implementing and assessing the T2BacteriaPanel in a clinical setting.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will carry out a prospective trial to evaluate the direct-from-blood test to enhance antibiotic usage and clinical interventions for bloodstream infection patients.

Approved by the US Food and Drug Administration (FDA), the diagnostic test can identify sepsis-causing bacterial pathogens directly from whole blood within three to five hours.

Designed to run on the fully automated T2Dx Instrument, the test simultaneously identifies five bacteria species: P. aeruginosa, E. coli, E. faecium, S. aureus and K. pneumoniae.

The CE-marked version identifies the aforesaid pathogens and A. baumannii.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

T2 Biosystems chairman and CEO John Sperzel said: “Vanderbilt University Medical Center is one of the leading healthcare institutions in the country and we are excited to partner with them to bring our life-saving sepsis pathogen detection products to their patients and providers.

“The Vanderbilt Learning Healthcare System Platform provides a unique opportunity to show the benefit of rapid, culture-independent diagnostics and further demonstrate the value of the T2Bacteria Panel in rapidly identifying causative bacterial pathogens in septic patients.”

Last month, the company submitted a 510(k) premarket notification with the US FDA for its T2Biothreat Panel.